Antidiabetic Effect of Urolithin A in Cultured L6 Myotubes and Type 2 Diabetic Model KK-Ay/Ta Mice with Glucose Intolerance
Current Issues in Molecular Biology · 24.01.2024 · 46 (2) · 1078-1090
DOI: 10.3390/cimb46020068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 24.01.2024. Verfasst von Shinji Kondo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Bioscience Research and Education, Utsunomiya University, Utsunomiya 321-8505, Tochigi, Japan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Ministry of Education, Culture, Sports, Science and Technology, Japan Society for the Promotion of Science (JSPS KAKENHI.
Abstract (Originalsprache)
Diabetes is caused by abnormal glucose metabolism, and muscle, the largest tissue in the human body, is largely involved. Urolithin A (UroA) is a major intestinal and microbial metabolite of ellagic acid and ellagitannins and is found in fruits such as strawberry and pomegranate. In this present study, we investigated the antidiabetic effects of UroA in L6 myotubes and in KK-Ay/Ta, a mouse model of type 2 diabetes (T2D). UroA treatment elevated the glucose uptake (GU) of L6 myotubes in the absence of insulin. This elevation in GU by UroA treatment was partially inhibited by the concurrent addition of LY294002, an inhibitor of phosphatidylinositol 3-kinase (PI3K) which activates Akt (PKB: protein kinase B) or Compound C, an inhibitor of 5′-adenosine monophosphate-activated protein kinase (AMPK). Moreover, UroA was found to activate both pathways of Akt and AMPK, and then to promote translocation of glucose transporter 4 (GLUT4) from the cytosol to the plasma membrane in L6 myotubes. Based on these in vitro findings, an intraperitoneal glucose tolerance test (IPGTT) was performed after the oral administration of UroA for 3 weeks to KK-Ay/Ta mice with glucose intolerance. UroA was demonstrated to alleviate glucose intolerance. These results suggest that UroA is a biofactor with antihyperglycemic effects in the T2D state.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Bioscience Research and Education, Utsunomiya University, Utsunomiya 321-8505, Tochigi, Japan.
- Department of Public Health, Dokkyo Medical University School of Medicine, Mibu 321-0293, Tochigi, Japan.
- School of Agriculture, Utsunomiya University, Utsunomiya 321-8505, Tochigi, Japan.
- United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, Fuchu 183-8509, Tokyo, Japan.
ORCID-Profile: Shinji Kondo, Fumiaki Yoshizawa, Kazumi Yagasaki
Förderung
- Japan Society for the Promotion of Science
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (JSPS KAKENHI
- Regional Innovation Strategy Support Program, MEXT, Japan
Zitieren
APA
Kondo, S., Adachi, S. I., Komatsu, W., Yoshizawa, F., & Yagasaki, K. (2024). Antidiabetic Effect of Urolithin A in Cultured L6 Myotubes and Type 2 Diabetic Model KK-Ay/Ta Mice with Glucose Intolerance. Current Issues in Molecular Biology, 46(2), 1078-1090. https://doi.org/10.3390/cimb46020068
Vancouver
Kondo S, Adachi SI, Komatsu W, Yoshizawa F, Yagasaki K. Antidiabetic Effect of Urolithin A in Cultured L6 Myotubes and Type 2 Diabetic Model KK-Ay/Ta Mice with Glucose Intolerance. Current Issues in Molecular Biology. 2024;46(2):1078-1090. doi:10.3390/cimb46020068
BibTeX
@article{Kondo2024,
author = {Kondo, Shinji and Adachi, Shin-Ichi and Komatsu, Wataru and Yoshizawa, Fumiaki and Yagasaki, Kazumi},
title = {Antidiabetic Effect of Urolithin A in Cultured L6 Myotubes and Type 2 Diabetic Model KK-Ay/Ta Mice with Glucose Intolerance},
journal = {Current Issues in Molecular Biology},
year = {2024},
volume = {46},
number = {2},
pages = {1078--1090},
doi = {10.3390/cimb46020068}
}
EUVIMED